Updates on Dengue Vaccine and Antiviral: Where Are We Heading?
Open Access
Abstract
Approximately 100–400 million people from more than 100 countries in the tropical and subtropical world are affected by dengue infections. Recent scientific breakthroughs have brought new insights into novel strategies for the production of dengue antivirals and vaccines. The search for specific dengue inhibitors is expanding, and the mechanisms for evaluating the efficacy of novel drugs are currently established, allowing for expedited translation into human trials. Furthermore, in the aftermath of the only FDA-approved vaccine, Dengvaxia, a safer and more effective dengue vaccine candidate is making its way through the clinical trials. Until an effective antiviral therapy and licensed vaccine are available, disease monitoring and vector population control will be the mainstays of dengue prevention. In this article, we highlighted recent advances made in the perspectives of efforts made recently, in dengue vaccine development and dengue antiviral drug.Keywords
Funding Information
- Research University Individual grant, Universiti Sains Malaysia (1001/CIPPM/ 8012305)
- Malaysian Ministry of Education, Higher Institution Centre of Excellence (HICoE) Grant (311/CIPPM/4401005)
This publication has 87 references indexed in Scilit:
- Allosteric Inhibition of the NS2B-NS3 Protease from Dengue VirusACS Chemical Biology, 2013
- Barriers to preclinical investigations of anti-dengue immunity and dengue pathogenesisNature Reviews Microbiology, 2013
- A Phase II, Randomized, Safety and Immunogenicity Study of a Re-Derived, Live-Attenuated Dengue Virus Vaccine in Healthy AdultsThe American Journal of Tropical Medicine and Hygiene, 2013
- Identification of a Novel Antiviral Inhibitor of the Flavivirus Guanylyltransferase EnzymeJournal of Virology, 2012
- The development of recombinant subunit envelope-based vaccines to protect against dengue virus induced diseaseVaccine, 2011
- DNA Vaccines against Dengue Virus Type 2 Based on Truncate Envelope Protein or Its Domain IIIPLOS ONE, 2011
- Immunogenicity and protective efficacy of a psoralen-inactivated dengue-1 virus vaccine candidate in Aotus nancymaae monkeysVaccine, 2011
- Domain III of the envelope protein as a dengue vaccine targetExpert Review of Vaccines, 2010
- Molecular targets for flavivirus drug discoveryAntiviral Research, 2009
- Development of a Purified, Inactivated, Dengue-2 Virus Vaccine Prototype in Vero Cells: Immunogenicity and Protection in Mice and Rhesus MonkeysThe Journal of Infectious Diseases, 1996